Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Non-cash Items (2018 - 2025)

Crinetics Pharmaceuticals (CRNX) has 8 years of Non-cash Items data on record, last reported at $7.5 million in Q2 2025.

  • For Q2 2025, Non-cash Items rose 28.52% year-over-year to $7.5 million; the TTM value through Jun 2025 reached $7.5 million, up 28.52%, while the annual FY2024 figure was $337.7 million, 60.88% up from the prior year.
  • Non-cash Items reached $7.5 million in Q2 2025 per CRNX's latest filing, up from $7.0 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $337.7 million in Q4 2024 and bottomed at $2172.0 in Q1 2021.
  • Average Non-cash Items over 5 years is $46.6 million, with a median of $10.9 million recorded in 2023.
  • Peak YoY movement for Non-cash Items: tumbled 99.99% in 2021, then skyrocketed 1996631.12% in 2022.
  • A 5-year view of Non-cash Items shows it stood at $80.9 million in 2021, then tumbled by 71.39% to $23.1 million in 2022, then surged by 806.67% to $209.9 million in 2023, then soared by 60.88% to $337.7 million in 2024, then crashed by 97.79% to $7.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-cash Items were $7.5 million in Q2 2025, $7.0 million in Q1 2025, and $337.7 million in Q4 2024.